Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Thursday. $210.75 million flowed into the stock on the tick-up and $344.62 million flowed out of the stock on the tick-down, for a money net flow of $133.87 million out of the stock. Of all companies tracked, Johnson & Johnson had the 2nd highest net out-flow for the day. Johnson & Johnson traded up $1.36 for the day and closed at $142.04

Several analysts have commented on the company. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a report on Thursday. Jefferies Group LLC raised their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday. Barclays PLC raised their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the company an “equal weight” rating in a report on Wednesday. Cowen and Company reissued an “outperform” rating and issued a $155.00 price objective (up from $147.00) on shares of Johnson & Johnson in a report on Wednesday. Finally, Morgan Stanley reissued a “hold” rating and issued a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a report on Wednesday. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $141.66.

The company has a market cap of $381.24 billion, a PE ratio of 24.70 and a beta of 0.78. The company has a 50-day moving average price of $133.17 and a 200 day moving average price of $130.54.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the company posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post $7.27 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.19% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. State Street Corp lifted its stake in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. FMR LLC lifted its stake in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the period. Finally, Capital World Investors lifted its stake in shares of Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the period. 65.90% of the stock is currently owned by institutional investors.

WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/19/traders-sell-johnson-johnson-jnj-on-strength-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.